Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 624,300 shares, a drop of 7.3% from the March 15th total of 673,600 shares. Based on an average trading volume of 240,900 shares, the short-interest ratio is […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
/PRNewswire/ Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers,.
Wall Street analysts forecast that Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) will report $80,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cardiff Oncology’s earnings. The highest sales estimate is $100,000.00 and the lowest is $50,000.00. Cardiff Oncology reported sales of $70,000.00 during the […]